The Patent Finder

Terms ending in 2043

Codiak Biosciences, Inc.

Every in-force patent on Codiak Biosciences, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,545,728Treatment of Cancer Metastasis by Targeting Exosome Proteins
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,758,896High-Throughput Chromatography Screening for Extracellular Vesicles
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,616,712Sting Agonist Comprising Exosomes for Treating Neuroimmunological Disorders
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,648,907Membrane Protein Scaffolds for Exosome Engineering
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,728,098Methods of Producing Extracellular Vesicles
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Codiak Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited